As such, future work entails the evaluation of synergetic combinations which potentiate current Ewing sarcoma chemotherapeutic cassettes to provide a clear strategy for further LSD1 inhibitor clinical trials which mitigate drug resistance and achieve maximal effect. The gene discussed is KDM1A; the disease is Ewing sarcoma.